|Ampio Pharmaceuticals Inc -- USA Stock|| |
USD 2.96 0.50 14.45%
Chief Regulatory Affairs Officer
Dr. Vaughan Lennox Clift, M.D., serves as Chief Regulatory Affairs Officer of Ampio Pharmaceuticals, Inc. Dr. Clift was employed as Ampios Chief Regulatory Affairs Officer from March 2010 until July 2016 and was employed by Life Sciences from May 2009 until March 2010. From 2005 to 2009, Dr. Clift was the chief executive officer of Detectachem LLC, a Houston, Texasbased manufacturer of a handheld explosive and narcotics detection device. Dr. Clift was the Vice President of Operations for Isolagen from 2002 until 2005.
The company has return on total asset (ROA)
of (65.37) %
which means that it has lost $65.37 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (253.19) %
meaning that it created substantial loss on money invested by shareholders.
Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado. Ampio Pharmaceuticals operates under Biotechnology classification in USA and traded on American Stock Exchange exchange. It employs 21 people.Ampio Pharmaceuticals Inc (AMPE) is traded on American Stock Exchange in USA. It is located in COLORADO, U.S.A and employs 21 people. Ampio Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.